TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06897839: Randomized, Double-Blind Parallel-Group, Adaptive, Three-Arm, Phase 2b/3 Multicenter Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preventing Bronchopulmonary Dysplasia (BPD) in High-Risk Preterm Neonat

Sponsor: Airway Therapeutics, Inc. · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 366 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,963,984

Rescue Site Savings

+$6,561,648

Unlock Full NCT06897839 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06897839 Rescue Dossier →